Wockhardt is a global pharmaceutical and biotechnology organisation, providing affordable, high-quality medicines for a healthier world. It is India’s leading research-based global healthcare enterprise with relevance in the fields of pharmaceuticals, biotechnology and a chain of advanced super speciality hospitals.
Wockhardt is a true Indian multi-national company with a multi-ethnic workforce of 8,600 Wockhardt associates from 21 different nationalities globally. It has 3 research centres and 12 manufacturing plants, with businesses ranging from the manufacture and marketing of pharmaceutical and bio-pharmaceutical formulations, active pharmaceutical ingredients (APIs) and vaccines.
Biotechnology has been a significant differentiator and has helped Wockhardt blaze new paths, and set goals that have impacted human life.
The biotechnology programme is geared towards a single objective - making high-quality affordable products that will take the benefits of this amazing science, to a large section of patients.
With very rich experience in mastering biotechnology research, they have built a competent organisation of skilled biotechnologists and ‘concept to market’ capabilities, in all facets of development and manufacture of recombinant biopharmaceuticals.
Wockhardt Ltd: Global pharmaceutical and biotechnology organisation
|2013||Wockhardt received the ‘Best Enterprise’ award from the Europe business assembly.|
|2011||Wockhardt and Shefield bio-science, USA announced a strategic alliance to distribute recombinant insulin in cell culture.|
|2009||Wockhardt won Government of India patent award.|
|2007||Wockhardt acquired Morton Grove in the US.|
|2004||Wockhardt Biotech Park was commissioned.|